Aceto Announces Rising Pharmaceuticals Subsidiary Launches Generic Version of Soma(R) Compound With Aspirin and Codeine Tablets and Generic Version of Decadron(R) Elixir PORT WASHINGTON, N.Y., April 11, 2012 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the marketing, sales and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generic subsidiary, has launched the 200mg/325 mg/16 mg strengths of Carisoprodol, Aspirin and Codeine phosphate Tablets USP, an approved generic version of Meda Pharmaceutical's Soma® Compound with Aspirin and Codeine Tablets, and 0.5mg/5ml strength of Dexamethasone Elixir USP, an approved generic version ofMerck & Co., Inc's., Decadron® Elixir, following the U.S. Food and Drug Administration (FDA) approval of both Abbreviated New Drug Applications (ANDA).According to IMS Health data, U.S. brand sales for Carisoprodol, Aspirin and Codeine tablets, which is used to relieve pain and muscle spasms, and Dexamethasone Elixir, which is a steroid used to treat severe allergies, arthritis and asthma, were approximately $5.8 Million collectively for the twelve months ended December, 2011. ABOUT ACETO Aceto Corporation, incorporated in 1947, is a global leader in the marketing and distribution of pharmaceutical intermediates and active ingredients, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals.With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries.Aceto's global operations, including a staff of 26 in China and 12 in India are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. (ACET-F) This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in Aceto's reports filed with the Securities and Exchange Commission, including, but not limited to, Aceto's Annual Report or Form 10-K for the fiscal year ended June 30, 2010 and other filings. Copies of these filings are available at www.sec.gov.Aceto undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise. CONTACT: For information contact: Theodore Ayvas Director of Corporate Communications & Investor Relations Aceto Corporation (516) 627-6000 www.aceto.com
Aceto Announces Rising Pharmaceuticals Subsidiary Launches Generic Version of Soma(R) Compound With Aspirin and Codeine Tablets
Press spacebar to pause and continue. Press esc to stop.